Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Natural History and Galsulfase Treatment in Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) — 10 Year Follow-up of Patients Who Previously Participated in an MPS VI Survey Study</title>
<author><name sortKey="Giugliani, Roberto" sort="Giugliani, Roberto" uniqKey="Giugliani R" first="Roberto" last="Giugliani">Roberto Giugliani</name>
<affiliation><nlm:aff id="A1">Medical Genetics Service, HCPA, Department of Genetics, UFRGS, and INAGEMP, Porto Alegre, Brazil</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lampe, Christina" sort="Lampe, Christina" uniqKey="Lampe C" first="Christina" last="Lampe">Christina Lampe</name>
<affiliation><nlm:aff id="A2">Department of Pediatric and Adolescent Medicine, Villa Metabolica, University Medical Center of the University of Mainz, Germany</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Guffon, Nathalie" sort="Guffon, Nathalie" uniqKey="Guffon N" first="Nathalie" last="Guffon">Nathalie Guffon</name>
<affiliation><nlm:aff id="A3">Hôpital Femme Mère Enfant, Bron, France</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Ketteridge, David" sort="Ketteridge, David" uniqKey="Ketteridge D" first="David" last="Ketteridge">David Ketteridge</name>
<affiliation><nlm:aff id="A4">Women’s and Children’s Hospital, North Adelaide, Australia</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Teles, Elisa Leao" sort="Teles, Elisa Leao" uniqKey="Teles E" first="Elisa Leão" last="Teles">Elisa Leão Teles</name>
<affiliation><nlm:aff id="A5">Hospital Pediátrico Integrado, Centro Hospitalar de S. João, Porto, Portugal</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wraith, James E" sort="Wraith, James E" uniqKey="Wraith J" first="James E." last="Wraith">James E. Wraith</name>
<affiliation><nlm:aff id="A6">Manchester Children’s Hospital, Centre for Genomic Medicine, St Mary’s Hospital, CMFT, University of Manchester, Manchester, UK</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Jones, Simon A" sort="Jones, Simon A" uniqKey="Jones S" first="Simon A" last="Jones">Simon A. Jones</name>
<affiliation><nlm:aff id="A6">Manchester Children’s Hospital, Centre for Genomic Medicine, St Mary’s Hospital, CMFT, University of Manchester, Manchester, UK</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Piscia Nichols, Cheri" sort="Piscia Nichols, Cheri" uniqKey="Piscia Nichols C" first="Cheri" last="Piscia-Nichols">Cheri Piscia-Nichols</name>
<affiliation><nlm:aff id="A7">BioMarin Pharmaceutical Inc., Novato, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lin, Ping" sort="Lin, Ping" uniqKey="Lin P" first="Ping" last="Lin">Ping Lin</name>
<affiliation><nlm:aff id="A7">BioMarin Pharmaceutical Inc., Novato, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Quartel, Adrian" sort="Quartel, Adrian" uniqKey="Quartel A" first="Adrian" last="Quartel">Adrian Quartel</name>
<affiliation><nlm:aff id="A7">BioMarin Pharmaceutical Inc., Novato, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Harmatz, Paul" sort="Harmatz, Paul" uniqKey="Harmatz P" first="Paul" last="Harmatz">Paul Harmatz</name>
<affiliation><nlm:aff id="A8">Children’s Hospital & Research Center Oakland, Oakland, CA, USA</nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">24764221</idno>
<idno type="pmc">4107078</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107078</idno>
<idno type="RBID">PMC:4107078</idno>
<idno type="doi">10.1002/ajmg.a.36584</idno>
<date when="2014">2014</date>
<idno type="wicri:Area/Pmc/Corpus">001E29</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001E29</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Natural History and Galsulfase Treatment in Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) — 10 Year Follow-up of Patients Who Previously Participated in an MPS VI Survey Study</title>
<author><name sortKey="Giugliani, Roberto" sort="Giugliani, Roberto" uniqKey="Giugliani R" first="Roberto" last="Giugliani">Roberto Giugliani</name>
<affiliation><nlm:aff id="A1">Medical Genetics Service, HCPA, Department of Genetics, UFRGS, and INAGEMP, Porto Alegre, Brazil</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lampe, Christina" sort="Lampe, Christina" uniqKey="Lampe C" first="Christina" last="Lampe">Christina Lampe</name>
<affiliation><nlm:aff id="A2">Department of Pediatric and Adolescent Medicine, Villa Metabolica, University Medical Center of the University of Mainz, Germany</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Guffon, Nathalie" sort="Guffon, Nathalie" uniqKey="Guffon N" first="Nathalie" last="Guffon">Nathalie Guffon</name>
<affiliation><nlm:aff id="A3">Hôpital Femme Mère Enfant, Bron, France</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Ketteridge, David" sort="Ketteridge, David" uniqKey="Ketteridge D" first="David" last="Ketteridge">David Ketteridge</name>
<affiliation><nlm:aff id="A4">Women’s and Children’s Hospital, North Adelaide, Australia</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Teles, Elisa Leao" sort="Teles, Elisa Leao" uniqKey="Teles E" first="Elisa Leão" last="Teles">Elisa Leão Teles</name>
<affiliation><nlm:aff id="A5">Hospital Pediátrico Integrado, Centro Hospitalar de S. João, Porto, Portugal</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wraith, James E" sort="Wraith, James E" uniqKey="Wraith J" first="James E." last="Wraith">James E. Wraith</name>
<affiliation><nlm:aff id="A6">Manchester Children’s Hospital, Centre for Genomic Medicine, St Mary’s Hospital, CMFT, University of Manchester, Manchester, UK</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Jones, Simon A" sort="Jones, Simon A" uniqKey="Jones S" first="Simon A" last="Jones">Simon A. Jones</name>
<affiliation><nlm:aff id="A6">Manchester Children’s Hospital, Centre for Genomic Medicine, St Mary’s Hospital, CMFT, University of Manchester, Manchester, UK</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Piscia Nichols, Cheri" sort="Piscia Nichols, Cheri" uniqKey="Piscia Nichols C" first="Cheri" last="Piscia-Nichols">Cheri Piscia-Nichols</name>
<affiliation><nlm:aff id="A7">BioMarin Pharmaceutical Inc., Novato, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Lin, Ping" sort="Lin, Ping" uniqKey="Lin P" first="Ping" last="Lin">Ping Lin</name>
<affiliation><nlm:aff id="A7">BioMarin Pharmaceutical Inc., Novato, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Quartel, Adrian" sort="Quartel, Adrian" uniqKey="Quartel A" first="Adrian" last="Quartel">Adrian Quartel</name>
<affiliation><nlm:aff id="A7">BioMarin Pharmaceutical Inc., Novato, CA, USA</nlm:aff>
</affiliation>
</author>
<author><name sortKey="Harmatz, Paul" sort="Harmatz, Paul" uniqKey="Harmatz P" first="Paul" last="Harmatz">Paul Harmatz</name>
<affiliation><nlm:aff id="A8">Children’s Hospital & Research Center Oakland, Oakland, CA, USA</nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">American journal of medical genetics. Part A</title>
<idno type="ISSN">1552-4825</idno>
<idno type="eISSN">1552-4833</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p id="P1">Mucopolysaccharidosis VI (MPS VI) is a clinically heterogeneous and progressive disorder with multiorgan manifestations caused by deficient N-acetlylgalactosamine-4-sulfatase activity. A cross-sectional Survey Study in individuals (n=121) affected with MPS VI was conducted between 2001–2002 to establish demographics, urinary glycosaminoglycan (GAG) levels, and clinical progression of disease. We conducted a Resurvey Study (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>
: NCT01387854) to obtain 10-year follow-up data, including medical histories and clinical assessments (n=59), and survival status over 12-years (n=117). Patients received a mean (SD) of 6.8 (2.2) years of galsulfase ERT between baseline (Survey Study) and follow-up. ERT patients increased in height by 20.4 cm in the 4–7 year-old baseline age group and by 16.8 cm in the 8–12 year-old baseline age group. ERT patients <13 years old demonstrated improvement in forced vital capacity (FVC) by 68% and forced expiratory volume in 1 second (FEV1) by 55%, and those ≥13 years old increased FVC by 12.8% and maintained FEV1. Patients with >200 µg/mg baseline uGAG levels increased FVC by 48% in the <13 year-old and by 15% in the ≥13 year-old baseline age group. ERT patients who completed the 6-minute walk test demonstrated a mean (SD) increase of 65.7 (100.6) m. Cardiac outcomes did not significantly improve or worsen. Observed mortality rate among naïve patients was 50% (7/14) and 16.5% (17/103) in the ERT group (unadjusted hazard ratio, 0.24; 95% CI, 0.10 to 0.59). Long-term galsulfase ERT was associated with improvements in pulmonary functions and endurance, stabilized cardiac function and increased survival.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">101235741</journal-id>
<journal-id journal-id-type="pubmed-jr-id">32200</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Med Genet A</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Med. Genet. A</journal-id>
<journal-title-group><journal-title>American journal of medical genetics. Part A</journal-title>
</journal-title-group>
<issn pub-type="ppub">1552-4825</issn>
<issn pub-type="epub">1552-4833</issn>
</journal-meta>
<article-meta><article-id pub-id-type="pmid">24764221</article-id>
<article-id pub-id-type="pmc">4107078</article-id>
<article-id pub-id-type="doi">10.1002/ajmg.a.36584</article-id>
<article-id pub-id-type="manuscript">NIHMS582299</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Article</subject>
</subj-group>
</article-categories>
<title-group><article-title>Natural History and Galsulfase Treatment in Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) — 10 Year Follow-up of Patients Who Previously Participated in an MPS VI Survey Study</article-title>
</title-group>
<contrib-group><contrib contrib-type="author"><name><surname>Giugliani</surname>
<given-names>Roberto</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lampe</surname>
<given-names>Christina</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Guffon</surname>
<given-names>Nathalie</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Ketteridge</surname>
<given-names>David</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Teles</surname>
<given-names>Elisa Leão</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Wraith</surname>
<given-names>James E.</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Jones</surname>
<given-names>Simon A</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Piscia-Nichols</surname>
<given-names>Cheri</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Lin</surname>
<given-names>Ping</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Quartel</surname>
<given-names>Adrian</given-names>
</name>
<xref ref-type="aff" rid="A7">7</xref>
</contrib>
<contrib contrib-type="author"><name><surname>Harmatz</surname>
<given-names>Paul</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>
Medical Genetics Service, HCPA, Department of Genetics, UFRGS, and INAGEMP, Porto Alegre, Brazil</aff>
<aff id="A2"><label>2</label>
Department of Pediatric and Adolescent Medicine, Villa Metabolica, University Medical Center of the University of Mainz, Germany</aff>
<aff id="A3"><label>3</label>
Hôpital Femme Mère Enfant, Bron, France</aff>
<aff id="A4"><label>4</label>
Women’s and Children’s Hospital, North Adelaide, Australia</aff>
<aff id="A5"><label>5</label>
Hospital Pediátrico Integrado, Centro Hospitalar de S. João, Porto, Portugal</aff>
<aff id="A6"><label>6</label>
Manchester Children’s Hospital, Centre for Genomic Medicine, St Mary’s Hospital, CMFT, University of Manchester, Manchester, UK</aff>
<aff id="A7"><label>7</label>
BioMarin Pharmaceutical Inc., Novato, CA, USA</aff>
<aff id="A8"><label>8</label>
Children’s Hospital & Research Center Oakland, Oakland, CA, USA</aff>
<author-notes><corresp id="cor1"><label>*</label>
<bold>CORRESPONDING AUTHOR: Roberto Giugliani, MD</bold>
, Medical Genetics Service, Hospital de Clinicas de Porto Alegre, Rua Ramiro Barcelos 2350, 90035-903 Porto Alegre, RS, Brazil, <email>rgiugliani@hcpa.ufrgs.br</email>
, Phone: 55-51-3359-6341, Fax: 55-51-3359-8010</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted"><day>23</day>
<month>5</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub"><day>24</day>
<month>4</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="ppub"><month>8</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="pmc-release"><day>01</day>
<month>8</month>
<year>2015</year>
</pub-date>
<volume>164</volume>
<issue>8</issue>
<fpage>1953</fpage>
<lpage>1964</lpage>
<pmc-comment>elocation-id from pubmed: 10.1002/ajmg.a.36584</pmc-comment>
<abstract><p id="P1">Mucopolysaccharidosis VI (MPS VI) is a clinically heterogeneous and progressive disorder with multiorgan manifestations caused by deficient N-acetlylgalactosamine-4-sulfatase activity. A cross-sectional Survey Study in individuals (n=121) affected with MPS VI was conducted between 2001–2002 to establish demographics, urinary glycosaminoglycan (GAG) levels, and clinical progression of disease. We conducted a Resurvey Study (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link>
: NCT01387854) to obtain 10-year follow-up data, including medical histories and clinical assessments (n=59), and survival status over 12-years (n=117). Patients received a mean (SD) of 6.8 (2.2) years of galsulfase ERT between baseline (Survey Study) and follow-up. ERT patients increased in height by 20.4 cm in the 4–7 year-old baseline age group and by 16.8 cm in the 8–12 year-old baseline age group. ERT patients <13 years old demonstrated improvement in forced vital capacity (FVC) by 68% and forced expiratory volume in 1 second (FEV1) by 55%, and those ≥13 years old increased FVC by 12.8% and maintained FEV1. Patients with >200 µg/mg baseline uGAG levels increased FVC by 48% in the <13 year-old and by 15% in the ≥13 year-old baseline age group. ERT patients who completed the 6-minute walk test demonstrated a mean (SD) increase of 65.7 (100.6) m. Cardiac outcomes did not significantly improve or worsen. Observed mortality rate among naïve patients was 50% (7/14) and 16.5% (17/103) in the ERT group (unadjusted hazard ratio, 0.24; 95% CI, 0.10 to 0.59). Long-term galsulfase ERT was associated with improvements in pulmonary functions and endurance, stabilized cardiac function and increased survival.</p>
</abstract>
<kwd-group><kwd>(MeSH)</kwd>
<kwd>Mucopolysaccharidosis VI</kwd>
<kwd>Maroteaux-Lamy syndrome</kwd>
<kwd>N-Acetylgalactosamine-4-Sulfatase</kwd>
<kwd>Enzyme Replacement Therapy</kwd>
<kwd>Follow-Up Studies</kwd>
<kwd>Multicenter Study [Publication Type]</kwd>
<kwd>Survival Rate</kwd>
<kwd>Exercise Tolerance</kwd>
<kwd>Respiratory Function Tests</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E298 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 001E298 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Pmc |étape= Corpus |type= RBID |clé= |texte= }}
![]() | This area was generated with Dilib version V0.6.33. | ![]() |